Skystar Bio Pharmaceutical Company announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2013. For the quarter, the company reported revenue of $11,335,145 against $8,870,848 a year ago. Income from operations was $4,546,248 against $2,288,531 a year ago. Income before provision for income taxes was $4,447,638 against $2,281,640 a year ago. Net income was $3,750,881 against $1,698,866 a year ago. Diluted earnings per share were $0.49 against $0.23 a year ago.

For the six months, the company reported revenue of $16,865,886 against $16,797,185 a year ago. Income from operations was $5,616,533 against $4,756,505 a year ago. Income before provision for income taxes was $5,481,655 against $4,655,362 a year ago. Net income was $4,463,614 against $3,603,620 a year ago. Diluted earnings per share were $0.59 against $0.48 a year ago.

The company reiterate its fiscal 2013 guidance to be in the range of $40 million to $45 million. The company expects solid revenue growth and expansion in fiscal 2014.